CLCM
XERS icon

Crawford Lake Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Crawford Lake Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-72,493
Closed -$4.16M – 80
2019
Q4 		$4.16M Buy
+72,493
New +$599K 0.63% 42

Other funds holding XERS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Crawford Lake Capital Management's XERS Position: Q1 2020 in Review

Crawford Lake Capital Management sold out of Xeris Biopharma Holdings (XERS) in Q1 2020, closing a stake of 72,493 shares — an estimated $4.16M sold.

Crawford Lake Capital Management first reported a position in XERS in Q4 2019 and held it in 1 quarter. The position peaked at $4.16M in Q4 2019. 67 funds tracked by Wall St. Rank hold XERS as of Q1 2020.

  • Crawford Lake Capital Management reported no remaining Xeris Biopharma Holdings position as of Q1 2020 after selling out during the quarter.
  • Crawford Lake Capital Management sold 72,493 Xeris Biopharma Holdings shares in Q1 2020, an estimated $4.16M.
  • Crawford Lake Capital Management first reported a position in Xeris Biopharma Holdings in Q4 2019 and held it in 1 quarter.
  • Crawford Lake Capital Management's Xeris Biopharma Holdings position peaked at $4.16M in Q4 2019.
  • 67 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2020.

Based on Crawford Lake Capital Management's 13F filing for Q1 2020, filed 15 May 2020.